Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study
Authors:
Open Access
- 3 March 2021
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 99 (5) , 300-309
Abstract
Background: Unresectable cholangiocarcinoma has a poor prognosis and treatment options are limited. Combined systemic and intrahepatic chemotherapy may improve local control and enable downsizing. The aim of this study was to determine the maximum tolerated dose (MTD) of intravenous gemcitabine combined with intravenous cisplatin and hepatic arterial infusion (HAI) with floxuridine (FUDR) in patients with unresectable intrahepatic or hilar cholangiocarcinoma. Methods: Twelve patients were treated within a 3 + 3 dose escalation algorithm with 600, 800, or 1,000 mg/m2 gemcitabine and predefined doses of cisplatin 25 mg/m2 on days 1 and 8, q21, for 4 cycles, and FUDR 0.2 mg/kg on days 1–14 as continuous HAI, q28, for 3 cycles. Safety and toxicity as well as resectability rates after 3 months and preliminary survival data are reported. Results: The determined MTD for gemcitabine was 800 mg/m2. Dose limiting toxicities were neutropenic fever and biliary tract infections. In total, 27% of the patients showed partial remission and 73% stable disease. Although none of the patients achieved resectability after 3 months, the 3-year overall survival rate was 33%, median overall survival 23.9 months (range 1–49), and median progression-free survival 10.1 months (range 2–40). Conclusions: Intravenous gemcitabine/cisplatin plus HAI-FUDR is feasible and appears effective for disease control. Larger prospective studies evaluating this triplet combination are warranted.Keywords
This publication has 27 references indexed in Scilit:
- Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic CholangiocarcinomaJAMA Oncology, 2020
- Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patientsCancer Chemotherapy and Pharmacology, 2017
- Current Status on Cholangiocarcinoma and Gallbladder CancerLiver Cancer, 2016
- The Comprehensive Complication IndexAnnals of Surgery, 2014
- Liver transplantation for cholangiocarcinomaTransplant International, 2010
- Implanted Hepatic Arterial Infusion PumpsThe Cancer Journal, 2010
- Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survivalAnnals of Oncology, 2009
- Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus documentGut, 2002
- Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United StatesHepatology, 2001
- Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells.1998